Aura Biosciences (NASDAQ:AURA) Issues Quarterly Earnings Results

Aura Biosciences (NASDAQ:AURA) posted its quarterly earnings data on Monday. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.09), Zacks reports.

Aura Biosciences Stock Down 6.7 %

NASDAQ AURA opened at $7.00 on Tuesday. Aura Biosciences has a twelve month low of $6.33 and a twelve month high of $12.38. The stock has a market cap of $349.66 million, a P/E ratio of -4.05 and a beta of 0.30. The company’s 50-day simple moving average is $7.65 and its 200 day simple moving average is $8.66.

Insiders Place Their Bets

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the transaction, the insider now owns 304,692 shares in the company, valued at $2,336,987.64. This represents a 4.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 23,045 shares of company stock worth $177,242 over the last quarter. Company insiders own 5.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on AURA. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Aura Biosciences in a research report on Monday. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.